Celltech in £1.53bn sale to Belgian biotech

Celltech, the UK's largest biotechnology company, is to be bought by UCB, a Belgian pharmaceutical and chemical group, for £1.53bn (€2.25bn) as Europe's bankers gear up for a wave of consolidation in the healthcare sector.

Lazard is advising UCB on the recommended 550p a share offer - a 27.8% premium to Monday's closing price of 430.5p - and would be the second largest European pharmaceutical transaction announced this year. The sector has seen 20 deals worth €100m ($120m) or more, according to Dealogic, the investment banking research firm, and more are in the pipeline.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump